Bratton Capital Management L.P. Invests $40.81 Billion in Aquestive Therapeutics, Inc. $AQST

Bratton Capital Management L.P. acquired a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 9,810,958 shares of the company’s stock, valued at approximately $40,813,585,000. Aquestive Therapeutics accounts for 100.0% of Bratton Capital Management L.P.’s investment portfolio, making the stock its largest position. Bratton Capital Management L.P. owned about 0.08% of Aquestive Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AQST. NewEdge Advisors LLC acquired a new position in Aquestive Therapeutics in the 3rd quarter worth about $28,000. BNP Paribas Financial Markets boosted its holdings in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after purchasing an additional 4,134 shares during the period. Modern Wealth Management LLC bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $33,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter valued at $42,000. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 103.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 264,000 shares in the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AQST has been the subject of several research reports. Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Oppenheimer initiated coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $8.50.

Insider Activity at Aquestive Therapeutics

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the sale, the director directly owned 25,000 shares in the company, valued at approximately $125,500. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by insiders.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST opened at $4.66 on Friday. The firm has a market cap of $584.88 million, a price-to-earnings ratio of -7.17 and a beta of 1.49. Aquestive Therapeutics, Inc. has a 52 week low of $2.93 and a 52 week high of $7.55. The firm has a 50-day moving average price of $4.18 and a two-hundred day moving average price of $4.12.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to analyst estimates of $11.42 million. As a group, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.